Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypertonic saline + epinephrine is a combination therapy consisting of a concentrated sodium chloride solution (typically 3% or higher) and the adrenergic agonist epinephrine. This combination is used in two main clinical contexts: - As a nebulized treatment for acute moderate bronchiolitis in infants, where it has been shown to reduce hospital stay and improve clinical severity scores compared to hypertonic saline alone[1][4][5][6]. - As an endoscopic local injection for hemostasis in upper gastrointestinal bleeding, where the mixture (commonly 3.6% or 7.1% sodium chloride with 0.005% epinephrine) is injected around bleeding vessels to arrest hemorrhage, particularly from gastric and duodenal ulcers[2]. Mechanistically, hypertonic saline acts osmotically to draw fluid out of edematous airway tissues or mucosa, while epinephrine stimulates alpha-adrenergic receptors causing vasoconstriction (reducing edema and bleeding), as well as beta-adrenergic receptors leading to bronchodilation[8]. The combination leverages both the physical effects of osmotic dehydration and the pharmacological effects of adrenergic stimulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hypertonic saline + epinephrine.